Molecular structure of TGF-β RI Kinase Inhibitor V, CAS Number: 627536-09-8
TGF-β RI Kinase Inhibitor V (CAS 627536-09-8)
See product citations (3)
Alternate Names:
2-(5-Chloro-2-fluorophenyl)pteridin-4-yl)pyridin-4-yl amine
Application:
TGF-β RI Kinase Inhibitor V is a TGF-β signaling blocker
CAS Number:
627536-09-8
Purity:
>97%
Molecular Weight:
352.75
Molecular Formula:
C17H10ClFN6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
TGF-beta RI Kinase Inhibitor V is a selective and reversible inhibitor, which suppresses TGF-beta RI/ALK5 signaling. It is known that TGF-beta RI Kinase Inhibitor V also inhibits p38alpha at concentrations greater than 867 nM. Studies indicate that TGF-betaRI Kinase Inhibitor V reduces the number of myofibroblasts at fibroblastic foci. In addition, this compound is effective in blocking autocrine and paracrine TGF-beta signaling in glioma cells and restores the lytic activity of polyclonal natural killer cells against glioma cells. This inhibitor functions in suppressing the action of MAPKAP and PKD.
TGF-β RI Kinase Inhibitor V (CAS 627536-09-8) References
- SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. | Uhl, M., et al. 2004. Cancer Res. 64: 7954-61. PMID: 15520202
- Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. | Hayashi, T., et al. 2004. Clin Cancer Res. 10: 7540-6. PMID: 15569984
- Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. | Jian, H., et al. 2006. Genes Dev. 20: 666-74. PMID: 16543220
- Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression. | Kapoun, AM., et al. 2006. Mol Pharmacol. 70: 518-31. PMID: 16707625
- Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. | Ge, R., et al. 2006. Clin Cancer Res. 12: 4315-30. PMID: 16857807
- Crosstalk between Shh and TGF-β signaling in cyclosporine-enhanced cell proliferation in human gingival fibroblasts. | Chung, Y. and Fu, E. 2013. PLoS One. 8: e70128. PMID: 23922933
- Role of Shh and TGF in cyclosporine-enhanced expression of collagen and α-SMA by gingival fibroblast. | Chung, Y., et al. 2015. J Clin Periodontol. 42: 29-36. PMID: 25385493
- Statins affect human glioblastoma and other cancers through TGF-β inhibition. | Xiao, A., et al. 2019. Oncotarget. 10: 1716-1728. PMID: 30899443
Inhibitor of:
β ig-h3, ACTR-IA, ACTR-IIB, AHNAK, Asporin, B7-H4, Blimp-1, C87499, C87977, CaMKIIγ, CRIM1, Cryptic, DAF-1, dsg1α, EMILIN-1, FGL1, FHL-2, FLRG, FOXC1, Fussel-18, G-CSFR, Gγ4, GDF-1, GDF-11, GDF-7, GDF-9, GDF-9B, GDF5OS, gremlin-1, gremlin-2, Hic-5, Inhibin β-A, Inhibin β-E, Integrin β8, LOC645781, LOC646862, LRRC32, LRRC70, LRRC72, Lumican, MAPKAPK, MAWDBP1, Nodal, NOMO, NOMO2, NPN, p38 alpha, PKD, PLAGL2, PMEPA1, PTGF-β, SARA, Ser/Thr Protein Kinase, Ski, Sm B/B′, Smad1, Smad2, Smad3, Smad4, Smad5, Smad7, Smad8, SNIP1, Swi3, Tβ-b, TBCK, TGF B-1, TGF B3, TGF beta, TGF beta 1, TGF beta RI, TGFα, TGFβ RII, TGFβ2, TGFβ3, TGIF2LX1, TGIF2LX2, TGTP2, TIAF-1, TIMAP, Trichohyalin, and Vasorin.Activator of:
ADMP, ALK-1, ARHGAP11B, ARHGAP8, CD109, cystatin E/M, DAF-7, EG546325, Lefty-2, MAWDBP1, Smad6, SnoN_SnoN2_SnoA, TGF B-1, TGFβ RIII, TGIF, TMEM100, TSC-22 D2, TSC-36, and WFIKKN.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TGF-β RI Kinase Inhibitor V, 2 mg | sc-203294 | 2 mg | $86.00 |